Evidence change feed

The record starts here.

A dated, sourced record of changes in guideline, regulatory, and payer evidence, mapped to rungs 5–7 of the recognition ladder. Changes are recorded after they occur, never predicted — this is a public record, not a forecast.

There are 4 entries so far, and it is worth being straight about what they are: each concerns how the public record itself is published and governed, rather than a change to any particular therapy. Those come as the watchlist resolves. The feed is published now, sparse, so it accumulates somewhere you can see rather than appearing fully formed later.

Discuss a Program RSS feed

Ladder position

Where recorded changes sit

Each entry maps to the recognition-ladder rung its change occurred at.

Rung 5 Guideline action Guideline committees revise recommendations, grades, or positioning.

Rung 6 Regulatory action Authorities update labels, indications, or approval status.

Rung 7 Payer/coverage action Payers change access, restrictions, or formulary placement.

Recorded changes

Dated, sourced evidence changes

Entries are recorded after they occur, newest first, each with a source link and a date. Entries recorded in the last quarter are marked recent.

2026-07-14 Rung 6 — Regulatory action Recent

FDA grants Breakthrough Therapy Designation for first-line sunvozertinib; sNDA submitted

AstraZeneca announced an exclusive global license from Dizal for sunvozertinib and confirmed that a supplemental NDA for the first-line EGFR exon 20 insertion indication has been submitted to the US FDA, which granted Breakthrough Therapy Designation in this setting.

Recorded as the observation input to registered forecast FF-001 (NCCN guideline listing). Observation only — no probability.

AstraZeneca

2026-05 Rung 5 — Guideline action Recent

NCCN adds free weekly guideline-change updates

NCCN introduced a free Guidelines Weekly Updates email alongside a paid Flash Updates tier, publishing what changed across its guideline library on a fixed cadence.

A public guideline-change delivery pattern now exists; it documents the change flow modeled as rung 5 transitions.

NCCN

2025-10 Rung 7 — Payer/coverage action

ICER publishes annual Launch Price and Access Report

ICER released its annual review of launch prices and access conditions — an independent, conflict-disclosed assessment of how new products enter coverage.

Independent assessments of access conditions are the reference standard for coverage-change records.

ICER

2025-01-07 Rung 6 — Regulatory action

FDA finalizes guidance on communicating scientific information about unapproved uses

FDA published its final guidance describing how firms may communicate truthful, non-misleading scientific information about unapproved uses, including requirements to keep sources unaltered, complete, and conflict-disclosed.

Sets the source-integrity standard that public evidence records are designed to meet.

FDA

Get told when something lands.

No schedule and no digest — the feed is too young to promise a cadence. You get an email when an entry is added, and nothing in between.